Roth Capital Issues Pessimistic Estimate for TLSI Earnings

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) – Equities researchers at Roth Capital cut their Q2 2025 earnings per share (EPS) estimates for shares of TriSalus Life Sciences in a report issued on Wednesday, May 21st. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of ($0.19) per share for the quarter, down from their previous forecast of ($0.11). The consensus estimate for TriSalus Life Sciences’ current full-year earnings is ($1.55) per share. Roth Capital also issued estimates for TriSalus Life Sciences’ Q3 2025 earnings at ($0.12) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.72) EPS and FY2026 earnings at ($0.29) EPS.

Other equities analysts also recently issued reports about the stock. Canaccord Genuity Group reiterated a “buy” rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, March 28th. Lake Street Capital initiated coverage on shares of TriSalus Life Sciences in a research report on Thursday, February 13th. They issued a “buy” rating and a $10.00 target price for the company. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $10.93.

TriSalus Life Sciences Stock Performance

Shares of TLSI stock opened at $5.56 on Friday. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $7.90. The stock has a market cap of $179.43 million, a price-to-earnings ratio of -2.23 and a beta of 0.50. The firm has a fifty day moving average of $5.42 and a 200-day moving average of $5.05.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The business had revenue of $9.17 million during the quarter, compared to analysts’ expectations of $9.04 million. During the same period last year, the business posted ($0.60) earnings per share.

Insider Buying and Selling

In other TriSalus Life Sciences news, insider Richard Marshak sold 6,597 shares of TriSalus Life Sciences stock in a transaction on Monday, May 19th. The shares were sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the sale, the insider now directly owns 69,101 shares of the company’s stock, valued at approximately $357,943.18. The trade was a 8.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 16,125 shares of company stock valued at $83,528 over the last 90 days. Company insiders own 27.50% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. bought a new stake in TriSalus Life Sciences during the 1st quarter valued at $187,000. Charles Schwab Investment Management Inc. acquired a new position in shares of TriSalus Life Sciences during the first quarter valued at about $55,000. Connective Capital Management LLC bought a new stake in shares of TriSalus Life Sciences during the fourth quarter worth about $140,000. Bridgeway Capital Management LLC raised its holdings in shares of TriSalus Life Sciences by 333.3% in the 4th quarter. Bridgeway Capital Management LLC now owns 65,000 shares of the company’s stock worth $326,000 after acquiring an additional 50,000 shares during the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of TriSalus Life Sciences by 120,471.6% in the 4th quarter. Bank of America Corp DE now owns 178,446 shares of the company’s stock worth $894,000 after acquiring an additional 178,298 shares during the last quarter. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.